SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending heavily as the community reacts to the DTCC's decision to utilize its blockchain for tokenizing traditional financial assets like stocks and government bonds. While some investors view this as a massive validation of Stellar's institutional utility, others are debating the sustainability of the price action, leading to intense discussions about potential short squeezes versus long-term valuation shifts.

KAIO provides institutional-grade real-world asset (RWA) tokenization infrastructure that seamlessly connects traditional investment funds with digital capital markets. Through its purpose-built protocol, KAIO enables leading global asset managers to issue and distribute regulated tokenized funds across multiple high-performance blockchain networks — including Ethereum, Sei, Hedera, Solana, Aptos, and others — significantly expanding global access to institutional-quality real-world asset strategies for qualified investors.   By tokenizing feeder structures and shares in flagship funds, KAIO brings onchain access to proven strategies such as the BlackRock ICS US Dollar Liquidity Fund (one of the world’s largest institutional money market funds), the Brevan Howard Master Fund, Hamilton Lane’s Senior Credit Opportunities Fund (SCOPE) via the HL SCOPE Access Fund, and Laser Digital’s Laser Carry Fund (LCF), among others. These tokenized vehicles deliver secure, compliant exposure to money market, macro, private credit, and alternative strategies while unlocking new levels of programmability, composability, and 24/7 liquidity in DeFi environments.

KAIO

KAIO is trending as traders speculate on a potential price reversal, citing its role in the real-world asset (RWA) space and visibility as a top gainer on Coinbase. Community sentiment remains divided between those aggressively accumulating during current price levels and others concerned by persistent downward momentum.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing a surge in community interest driven by recent Google research that highlights its architecture for post-quantum cryptographic security. Investors are actively debating the sustainability of this price momentum, with many highlighting its role in the emerging real-world asset and quantum-resistant blockchain narratives.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injective is gaining strong institutional momentum following significant fund inflows, a major treasury strategy update, and the filing of staked ETFs, all while the community increasingly views $NONJA.X as a leveraged, high-conviction play on the chain's DeFi and RWA growth.

Tidal Trust II - YieldMax Gold Miners Option Income Strategy ETF

YieldMax Gold Miners Option Income Strategy ETF

GDXY is trending as investors debate the sustainability of its high weekly distributions against ongoing NAV erosion caused by the volatility of gold miners. While some in the community highlight gold as a vital hedge against debt and geopolitical uncertainty, others are frustrated by the downward price action and are choosing to rotate capital into other assets.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently a focal point for investors as the community anticipates the upcoming ASCO plenary session on May 31, where critical overall survival data for its lung cancer therapy, ivonescimab, will be presented. While recent analyst downgrades have triggered volatility and sparked debate about trial results and competitive pressures, many in the community view these dips as buying opportunities, emphasizing the drug's clinical potential and the company's significant cash reserves ahead of late-stage milestones.

Memecoin on Injective taken over by the community.

Nonja

The community is rallying around $NONJA.X as a high-conviction, leveraged play on the Injective ecosystem, citing its strong liquidity, rug protection, and sustained growth despite broader market volatility. Investors are positioning for a potential cycle rotation, viewing the token as a primary beneficiary of Injective's fundamental strength and institutional adoption.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Investors are flocking to PSLV as a preferred physical-backed alternative to paper silver, driven by concerns over COMEX inventory levels and the structural supply-demand deficit. The community remains heavily focused on potential price decoupling between physical silver and paper-based ETFs, with many viewing dips as strategic accumulation opportunities amidst ongoing inflationary pressures and geopolitical instability.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending as market participants closely monitor the ongoing legal and commercial competition between Tyvaso DPI and Liquidia's Yutrepia, while investors await pivotal Phase 3 TETON-1 and TETON-2 data as major catalysts for the stock. The community remains focused on the company's long-term organ manufacturing pipeline and its strategic partnership with MannKind, which continues to drive discussions regarding royalty streams and future pipeline development.

Gap, Inc. operates as a global apparel retail company, which offers clothing, apparel, accessories, and personal care products for men, women, and children. The firm operates through the following segments: Gap Global, Old Navy Global, Banana Republic Global, Athleta, and Other. The Gap Global segment includes apparel and accessories for men and women under the Gap brand, along with the GapKids, BabyGap, GapMaternity, GapBody, and GapFit collections. The Old Navy Global segment offers clothing and accessories for adults and children. The Banana Republic Global segment provides clothing, eyewear, jewelry, shoes, handbags, and fragrances. The Athleta segment offers fitness apparel for women. The company founded by Donald G. Fisher and Doris F. Fisher in July 1969 and is headquartered in San Francisco, CA.

Gap, Inc.

Gap, Inc. is trending as investors react to a lowered full-year sales outlook and a disappointing first-quarter revenue miss that overshadowed steady gross margins. The community is actively debating the impact of operational stumbles at Old Navy, the potential for a holiday season rebound, and whether current market sentiment has created an oversold buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of +23.44% and +1.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +40.00% and +164.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally

Equity

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 


Why Is Plus Therapeutics Stock Gaining Friday?

Plus Therapeutics stock jumps after FDA grants Orphan Drug status to Reyobiq for pediatric brain cancer, boosting long-term outlook.read more...

Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9% - Here's Why

Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9% - Here's What Happened...

Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4

Plus (PSTV) delivered earnings and revenue surprises of +100.00% and +2.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +35.47% and +128.59%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Guardian Pharmacy Services (GRDN) Surpasses Q4 Earnings and Revenue Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +37.04% and +2.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +6.01% and +38.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Current Price	$5.82
Prev Close	$6.43
Open	$6.38
Dividend Yield	0.00%
50-Day Moving Average	$5.76
Beta	1.30
Avg. Volume	596,451.27
PE Ratio	-1.78

52-Week High	$23.43
52-Week Low	$2.90
Market Capitalization	$40.06M
EPS (Annual)	-$7.19
Price to Book	2.70
Revenue Per Employee	$186,178.57

PSTV
Plus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest PSTV News

PSTVPlus Therapeutics Inc